» Articles » PMID: 10798744

Tolerance Induced by Bone Marrow Chimerism Prevents Transplant Vascular Sclerosis in a Rat Model of Small Bowel Transplant Chronic Rejection

Overview
Journal Transplantation
Specialty General Surgery
Date 2000 May 8
PMID 10798744
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The major impediment to success in solid organ transplantation is chronic rejection (CR). The characteristic lesion of CR is transplant vascular sclerosis (TVS). Although the mechanism of TVS is thought to have an immunologic basis, in humans immunosuppression does not prevent or reverse it. One possible therapy to prevent TVS is induction of donor-specific tolerance. Bone marrow chimerism has been successful in inducing tolerance in acute and chronic rejection heart and kidney transplant models. The highly immunogenic small bowel (SB) allograft provides a rigorous test of the efficacy of this tolerance regimen. We examined whether induction of tolerance by bone marrow chimerism could prevent TVS in a model of Fisher 344 (F344) to Lewis (LEW) rat SB transplantation.

Methods: Bone marrow chimeras (BMC) were created by transplantation of T-cell-depleted F344 bone marrow into irradiated LEW rats. Chimerism was assessed by flow cytometric method. F344 SB, heterotopically transplanted into the chimeras, was clinically and histologically assessed for CR. F344 SB grafts, transplanted into cyclosporine-A-treated LEW recipients, served as control grafts for CR.

Results: Cyclosporine-A-treated LEW rats chronically rejected F344 SB grafts. By contrast, the BMC group demonstrated tolerance and had long-term SB graft survival (>120 days) without TVS. The BMC demonstrated immunocompetence by prompt rejection of third party ACI (RT1av1) SB allografts.

Conclusions: Bone marrow chimerism prevents chronic graft failure secondary to TVS in a model of chronic SB rejection. TVS fails to develop when tolerance is established, suggesting that the mechanisms involved in TVS are, in part, immunologically mediated.

Citing Articles

Rat Cytomegalovirus Vaccine Prevents Accelerated Chronic Rejection in CMV-Naïve Recipients of Infected Donor Allograft Hearts.

Streblow D, Hwee Y, Kreklywich C, Andoh T, Denton M, Smith P Am J Transplant. 2015; 15(7):1805-16.

PMID: 25766876 PMC: 5006870. DOI: 10.1111/ajt.13188.


Human cytomegalovirus-encoded pUL7 is a novel CEACAM1-like molecule responsible for promotion of angiogenesis.

MacManiman J, Meuser A, Botto S, Smith P, Liu F, Jarvis M mBio. 2014; 5(6):e02035.

PMID: 25352622 PMC: 4217178. DOI: 10.1128/mBio.02035-14.


Cytomegalovirus CC chemokine promotes immune cell migration.

Vomaske J, Denton M, Kreklywich C, Andoh T, Osborn J, Chen D J Virol. 2012; 86(21):11833-44.

PMID: 22915808 PMC: 3486311. DOI: 10.1128/JVI.00452-12.


RCMV increases intimal hyperplasia by inducing inflammation, MCP-1 expression and recruitment of adventitial cells to intima.

Grudzinska M, Bojakowski K, Soin J, Stassen F, Soderberg-Naucler C, Religa P Herpesviridae. 2011; 1(1):7.

PMID: 21429242 PMC: 3063229. DOI: 10.1186/2042-4280-1-7.


Cytomegalovirus latency promotes cardiac lymphoid neogenesis and accelerated allograft rejection in CMV naïve recipients.

Orloff S, Hwee Y, Kreklywich C, Andoh T, Hart E, Smith P Am J Transplant. 2011; 11(1):45-55.

PMID: 21199347 PMC: 3454525. DOI: 10.1111/j.1600-6143.2010.03365.x.